• English
    • français
  • Help
  •  | 
  • Contact
  •  | 
  • About
  •  | 
  • Login
  • HAL portal
  •  | 
  • Pages Pro
  • EN
  •  / 
  • FR
View Item 
  •   LillOA Home
  • Liste des unités
  • Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA) - ULR 7365
  • View Item
  •   LillOA Home
  • Liste des unités
  • Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA) - ULR 7365
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Allogeneic haematopoietic cell transplantation ...
  • BibTeX
  • CSV
  • Excel
  • RIS

Document type :
Article dans une revue scientifique
DOI :
10.1016/j.bulcan.2017.10.018
PMID :
29173980
Permalink :
http://hdl.handle.net/20.500.12210/4322
Title :
Allogeneic haematopoietic cell transplantation for diffuse large B cell lymphoma: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)
Author(s) :
Gauthier, Jordan [Auteur]
Chantepie, Sylvain [Auteur]
Bouabdallah, Krimo [Auteur]
Jost, Edgar [Auteur]
Nguyen, Stephanie [Auteur]
Gac, Anne-Claire [Auteur]
Damaj, Gandhi [Auteur]
Dulery, Remy [Auteur]
Michallet, Mauricette [Auteur]
Delage, Jeremy [Auteur]
Lewalle, Philippe [Auteur]
Morschhauser, Franck [Auteur] refId
Groupe de Recherche sur les formes Injectables et les Technologies Associées - ULR 7365 [GRITA]
Salles, Gilles [Auteur]
Yakoub-Agha, Ibrahim [Auteur] refId
Lille Inflammation Research International Center - U 995 [LIRIC]
Cornillon, Jerome [Auteur]
Journal title :
Bulletin du cancer
Abbreviated title :
Bull. Cancer
Volume number :
104
Pages :
S131-S135
Publication date :
2017
HAL domain(s) :
Sciences du Vivant [q-bio]
English abstract : [en]
Despite great improvements in the outcome of patients with lymphoma, some may still relapse or present with primary refractory disease. In these situations, allogeneic hematopoietic cell transplantation is a potentially ...
Show more >
Despite great improvements in the outcome of patients with lymphoma, some may still relapse or present with primary refractory disease. In these situations, allogeneic hematopoietic cell transplantation is a potentially curative option, this is true particularly in the case of after autologous stem cell transplantation if remission can be achieved. Recently, novel agents such as anti-PD1 and BTK inhibitors have started to challenge the use of allogeneic hematopoietic cell transplantation for relapsed or refractory lymphoma. During the 2016 annual workshop of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC), we performed a comprehensive review of the literature published in the last 10 years and established guidelines to clarify the indications and transplant modalities in this setting. This section specifically reports on our conclusions regarding diffuse large B cell lymphoma.Show less >
Language :
Anglais
Audience :
Internationale
Popular science :
Non
Administrative institution(s) :
Université de Lille
CHU Lille
Inserm
Collections :
  • Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA) - ULR 7365
  • Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Research team(s) :
Innovation/évaluation des médicaments injectables
Submission date :
2019-02-26T17:07:02Z
Université de Lille

Mentions légales
Université de Lille © 2017